JERRY KUNKEL: Open Payments
NPI 1548781164 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,794 in 104 payments from 17 companies in 2025. Trend: 2023 $1,449 · 2024 $4,530 · 2025 $5,794
Speaker / faculty: $3,700Food & beverage: $1,981Travel & lodging: $113
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $3,962 |
| Vanda Pharmaceuticals Inc. | 23 | $482 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $401 |
| Otsuka America Pharmaceutical, Inc. | 14 | $298 |
| Neurocrine BioSciences, Inc. | 4 | $166 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Lundbeck LLC | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Lilly USA, LLC | 3 | $48 |
| Novo Nordisk Inc | 3 | $47 |
Products named: VRAYLAR, CAPLYTA, REXULTI, HETLIOZ, FANAPT, INGREZZA, Auvelity, AUSTEDO XR.
Industry payments across KY — which companies pay providers there.
